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https://doi.org/10.1016/j.cell.2020.09.050SUMMARYThe SARS-CoV-2 pandemic has caused extreme human suffering and economic harm. We generated and
characterized a new mouse-adapted SARS-CoV-2 virus that captures multiple aspects of severe COVID-
19 disease in standard laboratorymice. This SARS-CoV-2model exhibits the spectrum ofmorbidity andmor-
tality of COVID-19 disease as well as aspects of host genetics, age, cellular tropisms, elevated Th1 cytokines,
and loss of surfactant expression and pulmonary function linked to pathological features of acute lung injury
(ALI) and acute respiratory distress syndrome (ARDS). This model can rapidly access existing mouse re-
sources to elucidate the role of host genetics, underlying molecular mechanisms governing SARS-CoV-2
pathogenesis, and the protective or pathogenic immune responses related to disease severity. The model
promises to provide a robust platform for studies of ALI and ARDS to evaluate vaccine and antiviral drug per-
formance, including in the most vulnerable populations (i.e., the aged) using standard laboratory mice.INTRODUCTION
Zoonotic coronaviruses (CoVs) are responsible for three epi-
demics in the 21st century, including severe acute respiratory
syndrome coronavirus (SARS-CoV) in 2003 and the ongoing
Middle East respiratory syndrome coronavirus (MERS-CoV) in
2012. In December 2019, a third novel CoV designated SARS-
CoV-2 emerged (Zhou et al., 2020b; Zhu et al., 2020) and has re-
sulted in a worldwide pandemic with over 25 million cases and
over 850,000 deaths in over 220 countries (Dong et al., 2020).
SARS-CoV-2 infection results in a complex clinical syndrome,
designated Coronavirus Disease 2019 (COVID-19), that causes
a range of clinical symptoms frommild to a severe disease asso-
ciated with acute lung injury (ALI) and the acute respiratory
distress syndrome (ARDS) (Guan et al., 2020). SARS-CoV-2
infection can also produce strokes, cardiac pathology, gastroin-
testinal disease, coagulopathy, and a hyperinflammatory shock
syndrome (Mao et al., 2020; Wichmann et al., 2020; Cheung
et al., 2020). The elderly, and those with underlying co-morbid-Cellities, are at increased risk of severe COVID-19 (Zhou et al.,
2020a) and death is most commonly linked to respiratory failure
due to ARDS (Rothan and Byrareddy, 2020; Li and Ma, 2020). In
fact, the mortality rate from COVID-19 ARDS approaches 40%–
50%, perhaps associated with a ‘‘cytokine storm’’ characterized
by elevated levels of interferon (IFN)-g, interleukin (IL)-18,
transforming growth factor b (TGF-b), IL-6, IP-10, monocyte che-
moattractant protein-1 (MCP-1), monokine-induced by inter-
feron-g (MIG), and IL-8 (Sinha et al., 2020).
SARS-CoV-2 uses the human angiotensin-converting enzyme
2 (hACE2) as a receptor for docking and entry into cells but is
incapable of using the murine ortholog (mACE2) receptor (Letko
et al., 2020; Zhou et al., 2020b). To generate SARS-CoV-2
mouse models, several groups have developed transgenic
mouse lines expressing hACE2, utilizing a variety of exogenous
(Jiang et al., 2020; Bao et al., 2020) or murine promoters (Sun
et al., 2020b), or by transduction using adenovirus (Sun et al.,
2020a; Hassan et al., 2020) or adeno-associated virus vectors
(Israelow et al., 2020), to generate productive infections.183, 1–16, November 12, 2020 ª 2020 Published by Elsevier Inc. 1
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ResourceAlthough each system has certain advantages (e.g., speed of
development), infection in vector-mediated or transgenic over-
expression models typically causes a mild alveolitis in the lung
and/or progression to fatal encephalitis (Menachery et al.,
2016; McCray et al., 2007; Butler et al., 2006; Jacomy et al.,
2006), rarely recapitulating the severe lung disease that is one
of the hallmarks of COVID-19 in humans, and/or produce a fatal
encephalitis. As such, it is critical to develop models that use
standard laboratory mice, reproduce age-dependent SARS-
CoV-2 susceptibility, target nasal epithelia and alveolar pneumo-
cytes, and develop the relevant pulmonary lesions of acute lung
injury (including pneumonitis, edema, necrotic debris, and hya-
line membrane formation) that are consistent with progression
to ARDS. Suchmodels, especially if available in standard labora-
tory mice, will accelerate studies of COVID-19 immune
pathologies, the function of host genes in regulating disease pro-
gression, and will provide a high-throughput screening platform
for evaluating antiviral drugs and vaccines.
In this study, we describe a lethal mouse model of mouse-
adapted SARS-CoV-2 (defined as SARS-CoV-2 MA10) patho-
genesis that recapitulates the age-related disease severity
observed in humans, ALI/ARDS, and death in wild-type BALB/
c mice. Like human infections, SARS-CoV-2 MA10 infection tar-
gets the conducting and distal airways, including airway epithe-
lial cells and AT2 cells in the terminal bronchi and alveoli, and
replicates in nasal olfactory epithelium sustentacular cells and
Bowman’s glands. The SARS-CoV-2 MA10 infection in BALB/c
mice induces lung disease characterized by damaged airway
epithelium, exfoliated cells in small airways, fibrin deposition, oc-
casional hyaline membrane formation, pulmonary edema, sur-
factant expression loss, and congestion that can progress to
ARDS, especially in aged animals. Many Th1 proinflammatory
cytokines were elevated after infection, including IL-6. Interest-
ingly, SARS-CoV-2 MA10 infection of C57BL/6J mice caused a
milder phenotype, whereas infection of immunodeficient type I
and II interferon receptor double knockout C57BL/6J mice re-
sulted in severe weight loss and morbidity. Notably, mice
vaccinated with viral vector-delivered SARS-CoV-2 spike were
protected from clinical disease and infection of the lung. The
development of SARS-CoV-2 MA10 provides a much-needed
standard laboratory mouse model that recapitulates the age-
related severity spectrum and acute lung injury phenotype
observed in human SARS-CoV-2 infections. It also provides a
robust model to mechanistically address novel questions in
COVID-19 immunity, pathogenesis, and vaccine and antiviral
drug performance inwild-type and genetically modified standard
laboratory mice.
RESULTS
Adaptation of SARS-CoV-2 MA via Serial Passaging
In Vivo
We previously developed a recombinant mouse adapted strain
of SARS-CoV-2 (SARS-CoV-2 MA) capable of utilizing mACE2
for viral entry by remodeling the spike and receptor binding inter-
face via reverse genetics (Dinnon et al., 2020). Although SARS-
CoV-2 MA mediated infection of wild-type mice, young adult
mice did not display the major clinical manifestations or hall-2 Cell 183, 1–16, November 12, 2020marks of ALI (Dinnon et al., 2020). To improve the model, we
used experimental evolution in vivo via serial passage of
SARS-CoV-2 MA in the lungs of young adult BALB/cAnNHsd
mice (herein referred to as ‘‘BALB/c’’ mice) every 2 days to select
for more virulent strains (Roberts et al., 2007). With passage, we
observed a linear decrease in body weight over time achieving
greater than 10% body weight loss on 2 days post infection
(dpi) by passage ten (P10) (Figure 1A). We confirmed the viru-
lence of the virus population generated at P10 using a plaque pu-
rified clonal isolate (SARS-CoV-2 MA10) from this passage in
young adult BALB/c mice (Figure 1B). Deep sequencing of
mouse lung’s total RNA from the 10 passages, plaque purified
SARS-CoV-2 MA10, and four additional plaque purified passage
10 viruses was performed to identify the changes responsible for
the increased pathogenicity and rare variants. In addition to the
spike Q498Y/P499T substitutions engineered into the parental
SARS-CoV-2 MA, SARS-CoV-2 MA10 included 5 additional
nucleotide changes, all resulting in nonsynonymous coding
changes (Figures 1C and 1D; Table S1). These mutations
emerged in an ordered fashion and include changes in nonstruc-
tural protein 4 (nsp4) (C9438T), nsp7 (A11847G), nsp8
(A12159G), spike (S; C23039A), and open reading frame 6
(ORF6; T27221C). Some sequence heterogeneity was observed
across the plaque purified viruses, although SARS-CoV-2 MA10
had the fewest mutations and most represented the viral popu-
lation found at passage 10 (Table S1). The SARS CoV-2 MA10
maintained the ability to utilize non-human primate ACE2 and
replicated and formed plaques in Vero E6 cells (Figure 1E),
consistent with utility for viral propagation and titration. Impor-
tantly, SARS-CoV-2 MA10 was also attenuated compared to
wild-type SARS-CoV-2 (SARS-CoV-2 WT) in primary human
bronchiolar epithelial cells (HBEs) (Figure 1F), suggesting
decreased fitness in human cells. Collectively, these observa-
tions led to the choice of SARS-CoV-2 MA10 for subsequent
studies.
SARS-CoV-2 MA10 Causes Acute Lung Injury in Young
BALB/c Mice
To gain insight into the dose-dependent pathogenic potential of
SARS-CoV-2 MA10, we performed dose ranging studies in 10-
week-old BALB/c mice infected with either PBS (mock), 105 pla-
que-forming unit (PFU) of the parental SARS-CoV-2 MA, or 102,
103, 104, and 105 PFU SARS-CoV-2MA10.We observed a dose-
dependent increase in morbidity andmortality over the course of
14 days with SARS-CoV-2 MA10 (Figure 2A). Mortality rates of
20% and 60% were recorded for infection with 104 and 105
PFU, respectively. Notably, infection with 102 PFU of SARS-
CoV-2 MA10 produced an increased weight loss as compared
to 105 PFU infections with the parental SARS-CoV-2 MA strain,
highlighting the increased pathogenicity gained through
passaging. To best capture severe disease phenotypes without
excessivemortality, we proceededwith 104 PFU of SARS-CoV-2
MA10 as the standard infection dose for young adult BALB/
c mice.
To characterize the pathogenesis of SARS-CoV-2 MA10 in
young BALB/c mice, we examined the kinetics of disease in
mice through 7 days post infection using an intranasal inocu-




Figure 1. SARS-CoV-2 MA Increases in Pathogenicity following Serial In Vivo Passaging in Mice
(A) Percent starting weight at 2 dpi of mice throughout serial passage of SARS-CoV-2 MA10 in 10- to 12-week-old BALB/c mice infected with 105 PFU SARS-
CoV-2 MA at passage 1, or blind titer for passages 2–10.
(B) 10-week-old BALB/c mice were mock-infected with PBS or infected with 105 PFU of plaque-purified virus from passage 10 in (A), SARS-CoV-2 MA10, and
monitored for weight loss. Data analyzed by mixed effects analysis followed by Sidak’s multiple comparisons.
(C) Table of mouse adaptations present in plaque purified SARS-CoV-2 MA10 relative to parental SARS-CoV-2 MA. WT, wild type; nsp, nonstructural protein;
ORF, open reading frame.
(D) Schematic of SARS-CoV-2 genome with locations of mouse adaptations from (C) shown.
(E and F) Single step growth curve of SARS-CoV-2 WT and SARS-CoV-2 MA10 in Vero E6 cells (E) or differentiated primary human bronchiolar airway epithelial
cells (HBE) (F). n = 3 for each group, sampled serially. Dotted line represents limit of detection. Log transformed data were analyzed by 2-factor ANOVA followed
by Sidak’s multiple corrections. Error bars represent SEM about the mean for (A) and (B) and SD about the mean for (E) and (F). *p < 0.05.
See also Table S1.
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Resourcerapidly lost weight and reached maximum weight loss at day 4
(losing 16% of starting weight) (Figure 2B). At 5 dpi, the weight
loss trajectories of infected mice diverged, with many mice
recovering body weight juxtaposed to mice that continued to
lose weight, collectively resulting in a 15% mortality rate (Fig-
ure 2C). At the time of necropsy, acute stage lung damage was
noted grossly as firm, red, heavy lobes that were scored based
on the extent of congestion-related discoloration (Sheahan
et al., 2020a) (indicative of edema and diffuse alveolar damage)
that peaked at 4 dpi and remained high through 7 dpi (Figure 2D).
Virus replication in the lung peaked 1–2 dpi and was absent in
most surviving mice by 7 dpi (Figure 2E). Viral replication in the
upper respiratory tract (measured by viral titer in the nasal cavity)
remained high on 1–3 dpi but was non-detectable in most mice
by 5 dpi (Figure 2F).
To gain insight into the impact of infection on lung physiology,
pulmonary function was measured over time via whole body
plethysmography (WBP). As compared to control mice, infected
mice exhibited a loss in pulmonary function as indicated by sig-
nificant changes in PenH and Rpef, measures of airway obstruc-tion, and EF50, a measurement of exhalation flow rate (Figures
2G–2I).
Histopathologic analyses at 2, 4, and 7 dpi revealed early
multifocal damage to conducting airway epithelia (including
bronchioles) that corresponded to viral antigen staining, which
was intense on 2 dpi, waned by 4 dpi, and was absent by 7 dpi
(Figure 2J). Often, bronchial damage progressed to segmental
epithelial denudation with an accumulation of inflammatory cells,
sloughed epithelial cells, cellular debris, fibrin deposition, and
plasma proteins in the airway lumens. Later post-SARS-CoV-2
MA10 infection, airway epithelia became hyperplastic with
regeneration. The distal alveolar ducts and sacs were markedly
altered by infection, displaying hallmarks of diffuse alveolar dam-
age (DAD) and multifocal positive labeling of pneumocytes for
viral antigen at early time points after infection. Histologic
changes included hypercellular thickening of the alveolar septae
caused by infiltrating immune cells, pneumocyte degeneration
and necrosis, congestion of small vessels and capillaries, endo-
thelial activation, increased neutrophils with extravasation,







Figure 2. SARS-CoV-2 MA10 Causes Acute Lung Injury in Young Adult BALB/c Mice
(A) 10-week-old female BALB/c mice (n = 5 per group) were mock-infected, infected with 105 PFU SARS-CoV-2 MA, or 102, 103, 104, and 105 PFU SARS-CoV-
2 MA10.
(B–L) 10-week-old female BALB/c mice were mock-infected (n = 47) or infected with 104 PFU SARS-CoV-2 MA10 (n = 59).
(B) Percent starting weight. Data analyzed by mixed effects analysis followed by Sidak’s multiple comparisons.
(C) Survival rate.
(D) Gross lung congestion score. Data analyzed by 2-factor ANOVA followed by Sidak’s multiple comparisons.
(E) Viral lung titer (mock-infected: 1 dpi: n = 6, 2 dpi: n = 7, 3 dpi: n = 6, 4 dpi: n = 7, 5 dpi: n = 6, 6 dpi: n = 6, 7 dpi: n = 9; SARS-CoV-2MA10-infected: 1 dpi: n = 7, 2
dpi: n = 10, 3 dpi: n = 7, 4 dpi: n = 10, 5 dpi: n = 7, 6 dpi: n = 7, 7 dpi: n = 9). Dotted line represents limit of detection. Undetected samples are plotted at half the limit
of detection. Log transformed data analyzed as in (D).
(F) Viral nasal cavity titer. Dotted line represents limit of detection. Undetected samples are plotted at half the limit of detection.
(G–I) Whole body plethysmography analysis of lung function parameters (10 mice per group at 0 dpi): PenH (G), Rpef (H), and EF50 (I). Data analyzed as in (B).
(legend continued on next page)
ll
4 Cell 183, 1–16, November 12, 2020
Please cite this article in press as: Leist et al., A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory
Mice, Cell (2020), https://doi.org/10.1016/j.cell.2020.09.050
Resource
ll
Please cite this article in press as: Leist et al., A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory
Mice, Cell (2020), https://doi.org/10.1016/j.cell.2020.09.050
Resourceorganization into hyaline membranes, and increased numbers of
alveolar macrophages. Although later time points featured
increased numbers of lymphocytes organizing around bronchi-
oles, lymphocytic cuffing was not a prominent pathologic feature
in comparison to findings induced by other respiratory viral path-
ogens. Importantly, the most severe, lingering damage over the
time course was in the alveolar region.
The pathology of SARS-CoV-2 MA10-infected lungs was
blindly quantified utilizing two metrics of ALI (Schmidt et al.,
2018; Matute-Bello et al., 2011). First, diffuse alveolar damage
(DAD) was assessed based on the degree of cellular sloughing
and necrosis. SARS-CoV-2 MA10 induced DAD as early as 2
dpi and was maintained through 7 dpi (Figure 2J). Second, the
American Thoracic Society (ATS) has generated a small animal
model ALI scoring scheme that assesses neutrophil presence
in the interstitium and alveolar space, hyaline membrane forma-
tion, protein accumulation, and alveolar septal thickening.
Consistent with DAD scores, ATS ALI scores were increased in
SARS-CoV-2 MA10-infected mice at 2 dpi and increased
through 7 dpi (Figure 2K). Immunohistochemistry (IHC) staining
for viral nucleocapsid revealed intense staining at 2 dpi and
lack of staining by 7 dpi (Figure 2L), consistent with the lung viral
titer data (Figure 2D). At 2 dpi, viral antigen was detected in con-
ducting airway epithelia and in the alveoli, consistent with alve-
olar type II pneumocyte distribution patterns.Increased Morbidity and Mortality in Old Mice after
SARS-CoV-2 MA10 Infection
Because SARS-CoV-2 and other emerging human coronavi-
ruses exhibit an age-dependent increase in disease severity,
we investigated whether SARS-CoV-2 MA10 infection of aged
mice resulted in an increased disease severity. In comparison
to young mice, 1-year-old mice were highly susceptible to
SARS-CoV-2 MA10, with high morbidity and nearly 100% mor-
tality when infected with 104 and 105 PFU (Figure 3A). Although
mice infected with 103 PFU rapidly lost weight with very few an-
imals surviving, those infected with 102 PFU did not exhibit dis-
ease signs and all survived, suggesting a threshold of virus >102
was necessary to cause significant disease in 1-year-old mice.
Accordingly, we selected the lowest dose that caused severe
disease (103 PFU) as the standard infection dose for 1-year-old
mice. With this dose, the kinetics of weight loss were similar to
young BALB/c mice. However, unlike infected young adult
mice, all aged mice continued to lose weight over time and ulti-
mately lost 30% of their starting weight, succumbing to infection
and/or reaching the criteria for humane euthanasia (Figure 3B).
Overall, we observed increased mortality starting on day 4 after
infection with only 15% survival by day 7 (Figure 3C). Thus,
data presented at late time points such as 6 or 7 dpi are biased
toward rare survivors.
Gross pathological evaluations at necropsy revealed macro-
scopically detectable discoloration of lung tissue that achieved(J and K) Blinded histopathological evaluation of lung damage using DAD scoring
CoV-2 MA10 infection. Data analyzed as in (D).
(L) Representative 2003 images of lungs from mock and SARS-CoV-2 MA10-infe
immunohistochemistry (IHC) labeling against SARS-CoV-2 nucleocapsid, counter
SEM about the mean. *p < 0.05.maximal severity on days 4 and 5 after infection (Figure 3D). Virus
replication in aged mice peaked 1 to 2 dpi (5.33 106 PFU/tissue
and 1.2 3 107 PFU/tissue, respectively), values similar to young
adult mice. In contrast with young adult mice, in which virus was
cleared by 7 dpi, significant levels of infectious virus remained in
the lungs of agedmice at later time points (Figure 3E). Low levels
of infectious viruswere present in the serum at 2 dpi (Figure S1A).
Minimal virus was found in the heart, which may reflect residual
virus from the serum, and virus was not detected in brain at the
time of peak lung titer (2 dpi) (Figure S1A). Viral protein was not
detected in the heart, liver, small intestine, kidney, or spleen (Fig-
ures S1B–S1F). Old mice also exhibited viral titers in the nasal
cavity over the first 3 days of infection (peak on 3 dpi at 2 3
104 PFU/tissue), consistent with young adult mice (Figure 3F).
Infection with SARS-CoV-2 MA10 also disturbed lung function
in agedmice in a similar, but more prolonged, manner compared
to young mice with significant changes in PenH, Rpef, and EF50
at 2–5 dpi (Figures 3G–3I).
Histological analyses revealed severe DAD and higher ATS ALI
scores at later time points throughout the lung in 1-year-old mice
(Figures 3J and 3K), consistent with the more pronounced inter-
stitial congestion, epithelial damage, immune cell infiltration, and
edema in the older animals (Figure 3L). Viral antigen was de-
tected in small airways and alveolar regions at 2 and 4 dpi (Fig-
ure 3L). Viral RNA was also detected in the olfactory epithelium
at 2 dpi (Figure 3M), concordant with nasal cavity viral titers (Fig-
ure 3F). At 4 dpi, the olfactory epithelium was severely damaged,
likely contributing to reduced nasal cavity viral titers, and infec-
tion had spread to the Bowman’s gland in the submucosa
(Figure 3F).
Many viral diseases are associated with a systemic cytokine
storm. We analyzed the chemokine and cytokine responses in
the serum and lungs of 1-year-old BALB/c mice at 2 and 4 dpi
(Figures S2A and S2B). At 2 dpi, several proinflammatory cyto-
kines were elevated in the lungs of SARS-CoV-2-infected
mice, whereas few were elevated systemically in the serum.
For instance, IL-6, IL-1a, IL-1b, TNF-a, MCP-1, and IFN-g were
highly elevated in the serum and/or lungs of infected mice,
similar to reports in humans (Sinha et al., 2020). It remains uncer-
tain as to whether these elevated cytokines contribute to severe
disease outcomes after infection.Ameliorated Disease and NoMortality in C57BL/6JMice
after SARS-CoV-2 MA10 Infection
C57BL/6 is the most commonly usedmouse strain and is the ge-
netic background for the majority of genetically engineered mice
(Bryant, 2011). Because host genetic background dependent
differences in disease susceptibility have been described for
many infectious diseases including SARS-CoV (Noll et al.,
2020; Rasmussen et al., 2014; Gralinski et al., 2015; Graham
et al., 2015; Manet et al., 2020), we evaluated SARS-CoV-2
MA10 infection in young adult C57BL/6J mice. In comparison(J) and ATS ALI scoring (K) systems on days 2, 4, and 7 after mock or SARS-
cted mice from (J) and (K). H&E shown in the top panels. Bottom panels show
stained with hematoxylin. Scale bars represent 200 mm. All error bars represent
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Resourceto BALB/c mice, 10-week-old C57BL/6J mice exhibited less se-
vere disease and only the two highest doses (104 and 105 PFU)
were associated with significant weight loss, but no mortality af-
ter infection (Figure 4A). Therefore, we performed a detailed
analysis of the 104 PFU infectious dose over 7 days for a direct
comparison between young BALB/c and C57BL/6J mice. After
infection with 104 PFU, C57BL/6J mice exhibited a transient
10%–15% weight loss (peaked on 3 dpi and 4 dpi) (Figure 4B)
without mortality (Figure 4C). Gross congestion scores in lungs
at the time of harvest never rose above a score of 1 (roughly
25% lung involvement) and declined from 3 dpi until 7 dpi (Fig-
ure 4D). A clear peak in viral replication in the lungswas observed
on 2 dpi (1.6 3 106 PFU/tissue) that was 1 order of magnitude
lower than peak titers observed in BALB/cmice. After 2 dpi, titers
decreased steadily and were not detectable by 7 dpi (Figure 4E).
In addition, viral loads in the nasal cavity were relatively low
through 3 dpi (2 3 103 to 1.2 3 104 PFU/tissue) and were unde-
tectable by 4 dpi (Figure 4F). Changes in lung function as
measured by WBP were similar in pattern for the two mouse
strains, but C57BL/6J mice exhibited restored lung function to
near baseline levels by 5 dpi, whereas abnormalities in BALB/c
mice persisted until 7 dpi (Figures 4G–4I). Similarly, the patterns
of histologic changes were equivalent in C57BL/6J mice to
young BALB/c mice (Figure 4L), but the magnitudes of the acute
lung injury scores were dramatically attenuated in C57BL/6J
mice (Figures 4J and 4K).SARS-CoV-2 MA10 Cellular Tropism
To characterize the tissue and cellular tropism of SARS-CoV-2
MA10, BALB/c mouse nasal and lung tissues were probed for
the SARS-CoV-2 viral nucleocapsid and tissue/cell type markers
by RNA in situ hybridization (ISH) and immunohistochemistry. In
the proximal conducting airways (e.g., trachea, bronchi), little, if
any, SARS-CoV-2 MA10 infection was identified. However,
robust viral infection was identified in terminal bronchioles that
connect to the alveolar spaces (Figures 5A and 5B). In the
SARS-CoV-2MA10-infected mouse terminal bronchiolar epithe-
lial region, expression of Scgb1a1, which is a secretory club cell
marker, largely disappeared whereas Foxj1, a ciliated cell
marker, persisted. IHC identified SARS-CoV-2 MA10 nucleo-Figure 3. SARS-CoV-2 MA10 Disease Is Severely Exacerbated in Old M
(A) 1-year old female BALB/cmice (n = 5 per group) weremock-infected (gray), infe
2 MA10. Dotted line represents 70% starting body weight.
(B–L) 1-year old female BALB/c mice were mock-infected (n = 51) or infected wi
(B) Percent starting weight. Dotted line represents 70% starting body weight. Data
(C) Survival rate. Analyzed by log-rank test.
(D) Gross lung congestion score. Data analyzed by 2-factor ANOVA followed by
(E) Lung viral titer (mock-infected: 1 dpi: n = 6, 2 dpi, n = 7; 3 dpi, n = 6; 4 dpi, n = 7;
2 dpi, n = 10; 3 dpi, n = 7; 4 dpi, n = 8; 5 dpi, n = 1; 6 dpi, n = 2; 7 dpi, n = 3.) Dotted li
of detection. Log transformed data analyzed as in (D).
(F) Viral nasal cavity titer. Dotted line represents limit of detection. Undetected s
(G–I) Whole body plethysmography analysis of lung function parameters (10 mic
(J and K) Blinded histopathological evaluation of lung damage using DAD scoring
CoV-2 MA10 infection. Data analyzed as in (D).
(L) Representative 2003 images of lungs frommock and SARS-CoV-2 MA10-infe
immunohistochemistry (IHC) labeling against SARS-CoV-2 nucleocapsid, counte
(M) Representative in situ hybridization images of viral RNA in nasal cavity from S
represent SEM about the mean. *p < 0.05.capsid expression in non-ciliated cells with occasional colocali-
zation with CCSP (Figures 3L and 5C), suggesting that secretory
club cells were infected by SARS-CoV-2 MA10 and subse-
quently lost Scgb1a1 expression. This cellular tropism of
SARS-CoV-2 MA10 is different in human airways, perhaps re-
flecting different cell levels for ACE2 expression between human
versus mice (i.e., ciliated versus secretory club), respectively
(Zhang et al., 2020b).
In alveoli, ISH studies of mock-infected mice identified the two
major epithelial cell types, i.e., AT1 (Ager expressing) and AT2
(Sftpc, Sftpb expressing) cells (Figures 5D and 5E). In SARS-
CoV-2 MA10-infected mice, Sftpc and Sftpb expression charac-
teristic of AT2 cells virtually disappeared, whereas Ager expres-
sion associated with AT1 cells persisted at 2 dpi. IHC identified
occasional cells expressing a third AT2 cell marker (LAMP3)
that also co-expressed the SARS-CoV-2 MA10 nucleocapsid
(Figure 3F). Collectively, the loss of surfactant protein tran-
scripts, but not AGER, staining and colocalization of a third
AT2 marker (LAMP3) with virus, argues for selective infection
by SARS-CoV-2 MA10 of AT2 in the alveolus. The finding that
SARS-CoV-2 MA10-infected AT2 cells suppressed expression
of selective cell-type-specific genes (e.g., Sftpc and Sftpb) is
consistent with findings in infected human AT2 cells in vitro.
The nasal cavity of the mouse is comprised of 50% respira-
tory epithelium and 50% olfactory epithelium (Chamanza and
Wright, 2015). As noted above (Figure 3M), SARS-CoV-2 MA10
RNA was detected in olfactory epithelium, as defined anatomi-
cally and by the olfactory sensory neuron marker (OSN) marker,
Uchl1 (Figure S3). Notably, viral RNA was not detected in cells
expressing Uchl1, indicating that SARS-CoV-2 MA10 likely in-
fected sustentacular cells rather than OSNs. The selective olfac-
tory infection by SARS-CoV-2 MA10 is likely associated with
altered olfactory function commonly observed in subjects with
COVID-19 (Wölfel et al., 2020; Lechien et al., 2020; Spinato
et al., 2020).Interferon Signaling Is Protective in SARS-CoV-2 MA10
Infection
Wenext testedwhether the pathogenic SARS-CoV-2MA10 virus
could be used with genetically deficient mice to elucidateice
cted with 105 PFU SARS-CoV-2MA, or 102, 103, 104, and 105 PFU SARS-CoV-
th 104 PFU SARS-CoV-2 MA10 (n = 65).
analyzed by mixed effects analysis followed by Sidak’s multiple comparisons.
Sidak’s multiple comparisons.
5 dpi, n = 6; 6 dpi, n = 6; 7 dpi,: n = 13; SARS-CoV-2MA10-infected: 1 dpi, n = 6;
ne represents limit of detection. Undetected samples are plotted at half the limit
amples are plotted at half the limit of detection.
e per group at 0 dpi): PenH (G), Rpef (H), and EF50 (I). Data analyzed as in (B).
(J) and ATS ALI scoring (K) systems on days 2, 4, and 7 after mock or SARS-
cted mice from (J) and (K). H&E is shown in the top panels. Bottom panels show
rstained with hematoxylin. Scale bars represent 200 mm.
ARS-CoV-2 MA10-infected mice. Scale bar represents 100 mm. All error bars










Figure 4. C57BL/6J Mice Display Less Severe Disease following SARS-CoV-2 MA10 Infection
(A) 10-week-old female C57BL/6J mice (n = 5 per group) were mock-infected, infected with 105 PFU SARS-CoV-2 MA, or 102, 103, 104, and 105 PFU SARS-CoV-
2 MA10.
(B–L) 10-week-old female BALB/c mice were mock-infected (n = 46) or infected with 104 PFU SARS-CoV-2 MA10 (n = 57).
(B) Percent starting weight. Data analyzed by mixed effects analysis followed by Sidak’s multiple comparisons.
(C) Survival rate.
(D) Gross lung congestion score. Data analyzed by 2-factor ANOVA followed by Sidak’s multiple comparisons.
(E) Viral lung titer of mice from (B) (mock-infected: 1 dpi, n = 6; 2 dpi, n = 7; 3 dpi, n = 5; 4 dpi, n = 7; 5 dpi, n = 6; 6 dpi, n = 6; 7 dpi, n = 8; SARS-CoV-2 MA10-
infected: 1 dpi, n = 7; 2 dpi, n = 8; 3 dpi, n = 7; 4 dpi, n = 10; 5 dpi, n = 4; 6 dpi, n = 7; 7 dpi, n = 11). Dotted line represents limit of detection. Undetected samples are
plotted at half the limit of detection. Log transformed data analyzed as in (D).
(legend continued on next page)
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Resourceaspects of underlying molecular pathways and networks that
regulate SARS-CoV-2 disease. Interferon signaling plays an
important role in controlling and regulating disease severity after
infection with many viruses, including coronaviruses (Mesev
et al., 2019; Israelow et al., 2020). SARS-CoV-2 has also been re-
ported to be sensitive to type I and III interferons in human cells
in vitro (Felgenhauer et al., 2020; Vanderheiden et al., 2020) and
mice in vivo (Israelow et al., 2020; Dinnon et al., 2020). Conse-
quently, we infected C57BL/6J mice lacking the type I and II
interferon receptors (IFNR DKO) and wild-type controls with
104 PFU of SARS-CoV-2 MA10. IFNR DKOmice were more sus-
ceptible to SARS-CoV-2 MA10 as indicated by the prolonged
weight loss compared to wild-type mice (Figure 6A). Animals
were harvested on planned harvest days. At 4 dpi, SARS-CoV-
2 MA10 IFNR DKO mice displayed much higher congestion
scores (Figure 6B), which were associated with higher viral titers
on 2 and 4 dpi in IFNRDKOmice (Figure 6C). These data suggest
that IFNs are important in limiting viral replication and assisting in
virus clearance in vivo. Consistent with these data, lung function
abnormalities were more pronounced and prolonged in infected
IFNR DKO mice (Figures 6C–6E).
SARS-CoV-2 MA10 Allows Rapid Evaluation of Medical
Counter Measurements
As previously shown for SARS-CoV-2 MA, mouse adapted viral
strains allow for rapid testing of prevention and intervention stra-
tegies (Dinnon et al., 2020). The SARS-CoV-2MA10murinemodel
adds tomeasurements of viral load the ability to evaluate changes
in clinical parameters (weight loss, lung function, and pathologic
changes) and mortality (Dinnon et al., 2020). Utilizing our previ-
ously described non-select BSL2 Venezuelan equine encephalitis
viral replicon particle (VRP) system (Agnihothram et al., 2018; Din-
non et al., 2020), 10-week-old young adult and 1-year-old
(‘‘aged’’) BALB/cmicewere immunized with 103 VRPs expressing
SARS-CoV-2WTspike (S), nucleocapsid (N), andGFPcontrol, fol-
lowed by a boost at 3 weeks, and challenged with SARS-CoV-2
MA104weeks post boost (7weeks post prime). Neutralization as-
says using nLuc expressing reporter virus revealed strongly
neutralizing activity in the serum frommice at 3 weeks post boost
from spike, but not serum from nucleocapsid or GFP vaccinated
mice (Figures 7A and S4A). Of note, older (1-year-old) animals ex-
hibited significantly reduced neutralization titers as compared to
10-week-old animals, capturing age related vaccine vulnerabil-
ities often observed in human populations (Figure S4B). Notably,
polyclonal sera had similar neutralization titers for both SARS-
CoV-2 and SARS-CoV-2 MA containing two of three receptor
binding domain changes present in MA10, suggesting that the
SARS-CoV-2MA10model can accurately be used to test vaccine
efficacy (Figure S4C). Only mice vaccinated with SARS-CoV-2
spike expressing VRPs exhibited disease protection as demon-(F) Viral nasal cavity titer. Dotted line represents limit of detection. Undetected sam
in (D).
(G–I) Whole body plethysmography analysis of lung function parameters (10 mic
(J and K) Blinded histopathological evaluation of lung damage using DAD scoring
CoV-2 MA10 infection. Data analyzed as in (B).
(L) Representative 2003 images of lungs from mock and SARS-CoV-2 MA10-infe
immunohistochemistry (IHC) labeling against SARS-CoV-2 nucleocapsid, counte
SEM about the mean. *p < 0.05.strated by an absence of reductions in in body weight, protection
fromdeath (Figures 7B, 7C, S4D, andS4E), and total elimination of
viral titers in the lower respiratory tract (lungs) (Figures 7D and
S4F). Only one old mouse had detectable lung titer, correspond-
ing to the mouse with the lowest serum neutralization titer.
Interestingly, viral titers were still detectable on 2 and 4 dpi after
infection in the nasal cavity of immunized young and oldmice (Fig-
ures 7E and S4G), suggesting that mucosal immunity in the nasal
cavity may be difficult to achieve by systemic immunization.
Importantly, significant improvements in lung function were
measured in both age groups in VRP-S vaccinated mice versus
VRP-GFP or VRP-N controls (Figures 7F–7H and S4H–S4J).
DISCUSSION
Mouse models of viral pathogenesis that faithfully recapitulate
aspects of human COVID-19 are needed to better understand
the underlying molecular mechanisms of disease and assess
the performance of medical countermeasures. Herein, we used
in vivo experimental evolution to select a mouse-adapted
SARS-CoV-2 strain, designated SARS-CoV-2 MA10, capable
of causing lethal disease in standard laboratory mice. Impor-
tantly, the pathogenic findings of SARS-CoV-2 MA10 increased
as a function of mouse age, mirroring age gradients observed in
humans (Rothan and Byrareddy, 2020; Li and Ma, 2020). The
cellular tropism of SARS-CoV-2 MA10 in the mouse respiratory
tract generally reflects that reported in humans (e.g., tropism
for AT2 cells and olfactory epithelia) (Hou et al., 2020). Different
from humans are the infected secretory (club) cells versus cili-
ated cells in the conducting airways. The high cytokine expres-
sion levels measured in the lungs and to a lesser extent serum
of aged animals are consistent with findings reported in humans
with ARDS (Song et al., 2020; Costela-Ruiz et al., 2020). Our data
also demonstrated that IFN signaling played an important role in
attenuating SARS-CoV-2 MA10 viral replication, disease
morbidity, and mortality, suggesting that human genetic varia-
tion in IFN pathway genes may in part mediate the wide variation
of clinical outcomes observed in human SARS-CoV-2 infections.
Finally, we provided evidence for the practical application of this
model to evaluate SARS-CoV-2 vaccine candidates, with VRP-S
immunization protecting and significantly limited viral growth
and disease severity in the lung of young and aged mice.
The increased virulence of SARS-CoV-2 MA10 was associ-
ated with five mutations acquired through passage in mice. In
contrast to SARS-CoV, which acquired nonsynonymous muta-
tions in nsp5, nsp9, nsp13, S, and M when generating mouse
adapted SARS-CoV MA15 (Roberts et al., 2007), the SARS-
CoV-2 MA10 mouse adaptations reflected amino acid changes
in nsp4, nsp7, nsp8, S, and ORF6. Like SARS-CoV MA15, the
severity of SARS-CoV-2 MA10 infection was partially attenuatedples are plotted at half the limit of detection. Log transformed data analyzed as
e per group at 0 dpi): PenH (G), Rpef (H), and EF50 (I). Data analyzed as in (B).
(J) and ATS ALI scoring (K) systems on days 2, 4, and 7 after mock or SARS-
cted mice from (J) and (K). H&E shown in the top panels. Bottom panels show
rstained with hematoxylin. Scale bars represent 200 mm. Error bars represent







Figure 5. SARS-CoV-2 MA10 Infects Secretory Club Cells of the Lower Respiratory Tract and Type II Pneumocytes
SARS-CoV-2MA10 cellular tropism in the lung was assessed by RNA in situ hybridization (ISH) or immunohistochemistry (IHC) in mock or infected female 1-year-
old BALB/c mice from Figure 3 at 2 dpi.
(A) ISH of lower airway epithelium. Scgb1a1 is a marker of secretory club cells. Foxj1 is amarker of ciliated cells. (Aii–Aiii) are same inset field with or without SARS-
CoV-2 RNA channel.
(B) ISH of terminal bronchiole epithelium. (Bii–Biii) are same field with or without SARS-CoV-2 RNA channel.
(C) IHC of terminal bronchiole epithelium. CCSP is a marker of secretory club cells. (Cii–Civ) are the same inset field as single color channels or merged (Civ).
(D and E) ISH of alveoli.Ager is amarker of type I pneumocytes. Sftpc andSftpb aremarkers of type II pneumocytes. (E) IHC of alveoli. LAMP3 is amarker of type II
pneumocytes. (Eii–Eiv) are the same inset field as single color channels or merged (Eiv). Scale bars represent 200 mm.
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Figure 6. Interferon Signaling Deficient
Mice Are More Susceptible to SARS-CoV-
2 MA10
10-week-old male and female type I and II inter-
feron receptor double knockout (IFNR DKO; n =
12 mock, n = 19 MA10) and wild-type (WT; n = 11
mock, n = 13 MA10) control mice were mock-in-
fected or infected with 104 PFU SARS-CoV-2
MA10.
(A) Percent starting weight. Data analyzed by
mixed effects analysis followed by Sidak’s multi-
ple comparisons. Statistical comparisons shown
between MA10-infected WT and MA10-infected
IFNR DKO mice.
(B) Gross lung congestion score of mice from (A).
Data analyzed by 2-factor ANOVA followed by
Tukey’s multiple comparisons.
(C) Viral lung titer of mice from (A) (mock-infected:
2 dpi, n = 6 WT and 5 IFNR DKO; 4 dpi, n = 6 WT
and 6 IFNR DKO: SARS-CoV-2 MA10-infected: 2
dpi, n = 8 WT and 6 IFNR DKO; 4 dpi, n = 10 WT
and 6 IFNR DKO). Dotted line represents limit of
detection. Undetected samples are plotted at half
the limit of detection. Log transformed data
analyzed via 2-factor ANOVA followed by Tukey’s
multiple comparisons.
(D–F) Whole body plethysmography analysis of
lung function parameters (6 mice per group at
0 dpi): PenH (D), Rpef (E), and EF50 (F). Data
analyzed using 2-factor ANOVA followed by Si-
dak’s multiple comparisons. Error bars represent
SEM about the mean. *p < 0.05.
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in susceptibility and resistance alleles can alter the trajectory of
disease and a model of moderate disease. Indeed, a similar in-
termediate disease phenotype with SARS-CoV MA15 infection
in C57BL/6 mice revealed host genes that play protective or
pathogenic roles in SARS-CoV disease severity (Gralinski
et al., 2013, 2018; Totura et al., 2015; Sheahan et al., 2008; Chan-
nappanavar et al., 2016).
With respect to thecontributionof the5newmutations identified
in SARS-CoV-2 MA10, two engineered (Q498Y, P499T) and one
evolved (Q493K) amino acid changewere noted in the S glycopro-
tein receptor binding domain, and the latter mutation is predicted
to enhance interactions with mouse ACE2 receptor via interaction
with residue N31. Other SARS-CoV-2 strains, which replicate but
do not produce clinical signs of disease in mice, have RBDmuta-
tions atQ498HorR493K, respectively (Wanget al., 2020;Guet al.,
2020). Like for the 2003 SARS-CoV mouse adapted strains (Frie-
man et al., 2012; Roberts et al., 2007), multiple mutational path-
waysexist toenhancevirus adaptation to themouse.Themutation
in ORF6 is also interesting, because ORF6 acts as an interferonantagonist that blocks nuclear import of
karyopherin 2 into the nucleus of the cell
(Frieman et al., 2007). Previous studies in
our lab demonstrated that deletion of
ORF6 attenuated virus pathogenesis, al-
lowing nuclear import of multiple tran-scription factors and enhanced host defense expression patterns
in immortalized human lung cells, Calu3 (Sims et al., 2013).
Although speculative, these data suggest that the SARS-CoV-2
MA10ORF6mutationmay enhance blockade of transcription fac-
tor nuclear import, resulting in dampened innate immune antiviral
gene expression in the mouse. Finally, mutations were noted in
nsp4, nsp7, and nsp8 that have known activities in endoplasmic
reticulumandGolgimembrane reorganization to formviral replica-
tion factories, as scaffolds for replicase and RNA primase func-
tions, and perhaps processivity activities, respectively (Fehr and
Perlman, 2015). Future mapping studies will determine the contri-
bution of each change to viral pathogenesis and host expression
patterns in young and aged mice.
Emerging CoVs like SARS-CoV, MERS-Co, and SARS-CoV-2
primarily infect cells lining the upper and lower respiratory tract
with damage that triggers the development of ALI, ARDS, and
end stage severe lung disease. In humans, many COVID-19 pa-
tients exhibit varying degrees of acute injury to airway and alve-
olar epithelial cells, with resultant fibrin deposition, edema, and
hyaline membrane formation. Subsequent hyperplasia of typeCell 183, 1–16, November 12, 2020 11
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Figure 7. Virus Replicon Particle Delivered Spike Vaccination Protects Old Mice from SARS-CoV-2 MA10 Challenge
1-year-old female BALB/cmice were vaccinated with 103 virus replicon particles (VRPs) expressing SARS-CoV-2 wild-type spike (S, n = 10), nucleocapsid (N, n =
10), or GFP (n = 10). Mice received a boost 3 weeks after prime immunization, and submandibular blood samples were taken to be analyzed via neutralization
assays. All mice were challenged 4 weeks after the boost immunization.
(A) Neutralization of SARS-CoV-2 WT by sera from vaccinated mice 3 weeks post boost. ID50, inhibitory concentration necessary to achieve 50% virus
neutralization. Dotted line represents limit of detection. Undetected samples are plotted at half the limit of detection. Log transformed data analyzed via 1-factor
ANOVA followed by Holm-Sidak’s multiple comparisons.
(B) Percent starting weight. Data analyzed by mixed effects analysis followed by Sidak’s multiple comparisons.
(C) Survival rate.
(D and E) Viral lung (D) and nasal cavity (E) titer of mice from (B). n = 5 for each group at each time point. Dotted line represents limit of detection. Undetected
samples are plotted at half the limit of detection. Log transformed data analyzed via 2-factor ANOVA followed by Dunnett’s multiple comparisons.
(F–H) Whole body plethysmography analysis of lung function parameters (n = 5 mice per group at 0dpi): PenH (F), Rpef (G), and EF50 (H). Data analyzed as in (B).
Error bars represent SEM about the mean. *p < 0.05.
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ResourceII pneumocytes, organizing phases of diffuse alveolar damage,
focal pulmonary microthrombi, and endothelialitis are also
observed in patients (Ackermann et al., 2020; Bradley et al.,
2020; Tian et al., 2020). Using established metrics to quantitate
pathological features of ALI and ARDS in SARS-CoV (Sheahan
et al., 2020b) and MERS-CoV (Sheahan et al., 2020a) mouse
models, the lung pathology for SARS-CoV-2 MA10 was quanti-
tated and demonstrated significant ALI and ARDS in an age-
related disease gradient. The loss of surfactant protein B and
C expression is also consistent with the development of ARDS
in SARS-CoV2 MA10-infected mice. Surfactant protein B
expression is absolutely required for postnatal lung function,
lung compliance, and survival in surfactant protein B knockout
mice (Clark et al., 1997; Weaver and Conkright, 2001), whereas
lung structure and function in surfactant protein C null mice is
normal. Future studies will need to address the real possibility
that SARS-CoV-2 MA10 may cause a respiratory distress syn-
drome (RDS) phenotype primarily associated with surfactant
deficiency and whether surfactant replacement therapy might
reverse SARS-CoV-2 disease severity when administered early
in the viral-dominated phase in mammals (Stevens and Sinkin,
2007; Koumbourlis and Motoyama, 2020). Surfactant protein
and RNA expressions are also reduced in lethal SARS-CoV
infection in mice, suggesting common mechanisms of respira-
tory distress across Sarbecoviruses (Gralinski et al., 2013).
The limited availability of transgenicmousemodels that can be
infected by SARS-CoV-2 has hindered testing of vaccines and12 Cell 183, 1–16, November 12, 2020therapeutics against this virus. Our data demonstrate that
despite the three mutations in the S RBD, alphavirus VRP vacci-
nation with wild-type full-length SARS-CoV-2 S elicited robust
neutralization titers against wild-type and SARS-CoV-2 MA10
parental strains. Importantly, these neutralization titers
completely protected against SARS-CoV-2 MA10 replication in
most mice, which correlated with reduced clinical disease
morbidity and mortality. Because aged human populations are
most vulnerable to SARS-CoV-2, the use of aged BALB/c or
C57BL/6J mice provides a readily available and robust measure
of COVID-19 vaccine efficacy. It is noteworthy that several
vaccines failed in aged mice challenged with the 2003 mouse-
adapted SARS-CoV strain, associated with enhanced Th2
pathology (Sheahan et al., 2011; Tseng et al., 2012). Using alpha-
virus VRP vectors that drive strong neutralizing antibody re-
sponses and Th1 immune responses (Agnihothram et al.,
2018), enhanced disease phenotypes were not observed in
SARS-CoV-2 MA10-infected aged animals, supporting the
importance of vaccines that drive strong Th1 immunity and
neutralizing titers to prevent deleterious immune outcomes after
vaccination (Bolles et al., 2011; Corbett et al., 2020).
Notably, SARS-CoV-2 replicated efficiently in the nasal cavity
of the mice, primarily targeting the olfactory epithelium, where
sustentacular and Bowman’s gland cells, but not olfactory neu-
rons, express viral entry components, and support olfactory
neuron function (Gupta et al., 2020). Unlike reports in hamsters,
replication in mouse olfactory neurons was not evident (Zhang
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relationships between infection of sustentacular cells and che-
mosensory dysfunction in rodents. Because efficient SARS-
CoV-2 transmission may well be associated with efficient high
titer replication in the nasal cavity and oral pharynx, the SARS-
CoV-2 MA10 model provides an important tool for evaluating
vaccine and therapeutic performance in the upper respiratory
tract. Our VRP vaccine platform provided limited protection in
the nasal cavity of aged mice, suggesting an inability to prevent
infection in mucosal as compared to alveolar sites. Because S-
IgA antibodies in the secretions of the upper respiratory tract
and in saliva appear to result primarily from antigenic stimulation
of organized lymphoid follicles of the local mucosa (e.g., pharyn-
geal, palatine, and lingual tonsils), these data suggest that intra-
nasal vaccination may offer a strategy to protect from upper res-
piratory SARS-CoV-2 infection (Quiding-Järbrink et al., 1995).
SARS-CoV-2 infection in hamsters results in moderate weight
loss and lung pathology (Sia et al., 2020), whereas infections in
primates are typically minimally symptomatic (Rockx et al.,
2020). Both models provide important metrics for evaluating
vaccines and therapeutics and identifying host expression sig-
natures of infection. Although a variety of SARS-CoV-2 mouse
models have been reported, these models may have more
limited use for studies of alveolar disease pathogenesis. The
SARS-CoV-2 MA10 model captures multiple aspects of the
COVID-19 syndrome, including a spectrum of morbidity and
mortality determined by host genetics and increasing age, and
severe pathological features of ALI/ARDS, and corresponding
defects in lung function. Accordingly, this model provides the
global research community with a robust tool to elucidate the un-
derlying host genetics and molecular mechanisms governing
SARS-CoV-2 disease pathogenesis, host expression networks,
and immunity after infection. Intermediate disease phenotypes
in C57BL/6J mice also provide novel opportunities for using ex-
isting mutant mouse resources to determine the role of genes in
protective or pathogenic disease outcomes as a function of age.
Finally, the capacity tomeasure vaccine and therapeutic efficacy
in high-throughput lethal mouse models of acute lung injury and
ARDSmay provide critical insights into therapeutic agent perfor-
mance in the most vulnerable populations (e.g., the elderly and/
or in mouse models of the underlying co-morbidities) that
contribute to COVID-19 severity.STAR+METHODS
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Autopsy Findings and Venous Thromboembolism in Patients With COVID-19:
A Prospective Cohort Study. Ann. Intern. Med. 173, 268–277.Cell 183, 1–16, November 12, 2020 15
ll
Please cite this article in press as: Leist et al., A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory
Mice, Cell (2020), https://doi.org/10.1016/j.cell.2020.09.050
ResourceWölfel, R., Corman, V.M., Guggemos, W., Seilmaier, M., Zange, S., Müller,
M.A., Niemeyer, D., Jones, T.C., Vollmar, P., Rothe, C., et al. (2020). Virological
assessment of hospitalized patients with COVID-2019. Nature 581, 465–469.
Zhang, A.J., Lee, A.C., Chu, H., Chan, J.F., Fan, Z., Li, C., Liu, F., Chen, Y.,
Yuan, S., Poon, V.K., et al. (2020a). SARS-CoV-2 infects and damages the
mature and immature olfactory sensory neurons of hamsters. Clin. Infect.
Dis. Published online July 15, 2020. https://doi.org/10.1093/cid/ciaa995.
Zhang, H., Rostami, M.R., Leopold, P.L., Mezey, J.G., O’Beirne, S.L., Strulo-
vici-Barel, Y., and Crystal, R.G. (2020b). Expression of the SARS-CoV-2
ACE2 Receptor in the Human Airway Epithelium. Am. J. Respir. Crit. Care
Med. 202, 219–229.16 Cell 183, 1–16, November 12, 2020Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B.,
Gu, X., et al. (2020a). Clinical course and risk factors for mortality of adult inpa-
tients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet
395, 1054–1062.
Zhou, P., Yang, X.L., Wang, X.G., Hu, B., Zhang, L., Zhang, W., Si, H.R., Zhu,
Y., Li, B., Huang, C.L., et al. (2020b). A pneumonia outbreak associated with a
new coronavirus of probable bat origin. Nature 579, 270–273.
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B.,
Shi, W., Lu, R., et al.; China Novel Coronavirus Investigating and Research
Team (2020). A Novel Coronavirus from Patients with Pneumonia in China,
2019. N. Engl. J. Med. 382, 727–733.
ll
Please cite this article in press as: Leist et al., A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory
Mice, Cell (2020), https://doi.org/10.1016/j.cell.2020.09.050




Novus Biologicals Cat#: NB100-56576; RRID: AB_838838
Rabbit polyclonal SARS coronavirus
nucleocapsid, dilution at 1:500
Invitrogen Cat#: PA1-41098 RRID: AB_1087200
Goat anti-CCSP, dilution at 1:3000 Sigma-Aldrich Cat#: ABS1673
Rat DC-LAMP (LAMP3) antibody, dilution
at 1:100
NOVUS Biologicals Cat#: DDX0191P-100; RRID: AB_2827532
Donkey anti-Rabbit IgG (H+L) Highly Cross-
Adsorbed Secondary Antibody, Alexa Fluor
555, dilution at 1:1000
Invitrogen Cat#: AB_162543; RRID: AB_162543
Donkey anti-Rat IgG (H+L) Highly Cross-
Adsorbed Secondary Antibody, Alexa Fluor
488, dilution at 1:1000
Invitrogen Cat#: AB_2535794; RRID: AB_2535794
Donkey anti-Goat IgG (H+L) Cross-
Adsorbed Secondary Antibody, Alexa Fluor
647, dilution at 1:1000
Thermo Fisher Scientific Cat#: AB_2535864; RRID: AB_2535864
Discovery OmniMap anti Rabbit HRP Ventana, Roche Cat#: 760-4311; RRID: AB_2811043
Bacterial and Virus Strains
icSARS-CoV-2 WT Hou et al., 2020 N/A
icSARS-CoV-2 MA Dinnon et al., 2020 GenBank: MT844088
SARS-CoV-2 MA10 This paper GenBank: MT952602
icSARS-CoV-2-nLuc Dinnon et al., 2020 GenBank: MT844089
Chemicals, Peptides, and Recombinant Proteins
TRIzol Reagent ThermoFisher Cat#: 15596026
Critical Commercial Assays
Direct-zol RNA Miniprep Zymo Research Cat#: R2051
NEBNext Ultra II Non-directional RNA
Second Strand Synthesis Module
New England BioLabs Cat#: E6111S
Qubit dsDNA HS Assay Kit ThermoFisher Scientific Cat#: Q32851
Nextera XT DNA Library Preparation Kits Illumina Cat#: FC-131-1096
BioPlex Pro mouse cytokine 23-plex assay Bio-Rad Cat#: M60009RDPD
Nano-Glo Luciferase Assay Promega Cat#: N1130
RNAScope Multiplex Fluorescent Reagent
Kit v2
ACD Cat#: 323100
RNAScope probe SARS-CoV-2, S gene
encoding the spike protein (channel 1, 2,
and 3)
ACD Cat#: 848561
RNAScope probe Ager (channel 1) ACD Cat#: 550791
RNAScope probe Sftpc (channel 2) ACD Cat#: 314101-C2
RNAScope probe Foxj1 (channel 2) ACD Cat#: 317091-C2
RNAScope probe Scgb1a1 (channel 3) ACD Cat#: 420351-C3
Vector TrueVIEW Autofluorescence
Quenching Kit
Vector Laboratories Cat#: SP-8400
(Continued on next page)
Cell 183, 1–16.e1–e6, November 12, 2020 e1
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Deposited Data
Mouse lung total RNA – passage 1 This paper NCBI Bioproject PRJNA661544
Mouse lung total RNA – passage 2 This paper NCBI Bioproject PRJNA661544
Mouse lung total RNA – passage 3 This paper NCBI Bioproject PRJNA661544
Mouse lung total RNA – passage 4 This paper NCBI Bioproject PRJNA661544
Mouse lung total RNA – passage 5 This paper NCBI Bioproject PRJNA661544
Mouse lung total RNA – passage 6 This paper NCBI Bioproject PRJNA661544
Mouse lung total RNA – passage 7 This paper NCBI Bioproject PRJNA661544
Mouse lung total RNA – passage 8 This paper NCBI Bioproject PRJNA661544
Mouse lung total RNA – passage 9 This paper NCBI Bioproject PRJNA661544
Mouse lung total RNA – passage 10 This paper NCBI Bioproject PRJNA661544
Plaque purified cell culture supernatant
RNA – Passage 10 plaque 1
This paper NCBI Bioproject PRJNA661544
Plaque purified cell culture supernatant
RNA – Passage 10 plaque 2
This paper NCBI Bioproject PRJNA661544
Plaque purified cell culture supernatant
RNA – Passage 10 plaque 3
This paper NCBI Bioproject PRJNA661544
Plaque purified cell culture supernatant
RNA – Passage 10 plaque 4
This paper NCBI Bioproject PRJNA661544
Plaque purified cell culture supernatant
RNA – Passage 10 plaque 5 (SARS-CoV-
2 MA10)
This paper NCBI Bioproject PRJNA661544
Experimental Models: Cell Lines
Simian kidney Vero E6 ATCC Cat#: CRL1586; RRID: CVCL_0574
Human bronchiolar airway epithelial
cells (HBE)
Marsico Lung Institute (University of North
Carolina at Chapel Hill)
N/A
Experimental Models: Organisms/Strains
Mouse: BALB/c: BALB/cAnNHsd Envigo Strain 047
Mouse: C57BL/6J Jackson Laboratory Strain 000664
Mouse: IFNR DKO Whitmire Laboratory (University of North
Carolina at Chapel Hill)
N/A
Oligonucleotides
Random Primer 9 New England BioLabs Cat#: S1254S
Software and Algorithms
CLC Genomics Workbench (Version 12) QIAGEN https://digitalinsights.qiagen.com/
downloads/product-downloads/
FinePointe (Version 2.3.1.16) DSI Buxco respiratory solutions, DSI Inc. https://www.datasci.com/products/
software/finepointe-software
xPONENT Luminex https://www.luminexcorp.com/xponent/
cellSens Entry (Version 3.1) Olympus https://www.olympus-lifescience.com/en/
software/cellsens/
GraphPad Prism (Version 8.4.3) GraphPad https://www.graphpad.com
Adobe Illustrator (Version 24.2.3) Adobe https://www.adobe.com/products/
illustrator.html
Olyvia (Version 3.1.1) Olympus https://olympus-lifescience.com
Other
NanoDropTM One/OneC Microvolume UV-
Vis Spectrophotometer
Thermo Fisher Scientific Cat#: 840-329700
NovaSeq 6000 system Illumina https://www.illumina.com/systems/
sequencing-platforms/novaseq.html
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Whole body plethysmography machine DSI Buxco respiratory solutions, DSI Inc. https://www.datasci.com/products/
buxco-respiratory-products/
finepointe-whole-body-plethysmography
MAGPIX machine Luminex https://www.luminexcorp.com/
magpix-system/
Leica ASP 6025 Leica https://www.leicabiosystems.com/
histology-equipment/tissue-processors/
asp6025-s/
Leica Paraplast Leica Cat#: 39601006
Ventana Discovery platform Roche https://diagnostics.roche.com/us/en/
products/instruments/discovery-ultra.html
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ResourceRESOURCE AVAILABILITY
Lead Contact
Reagents and resources will be available under material transfer agreements and upon request to the Lead Contact, Ralph S. Baric
(rbaric@email.unc.edu).
Material Availability
Material and reagents generated in this study will be made available upon installment of a material transfer agreement (MTA).
Data and Code Availability
Genomic sequence of SARS-CoV-2 MA10, which was generated in this study, has been deposited to GenBank : MT952602).
Passaging and plaque purified deep sequencing data have been uploaded to NCBI Bioproject: PRJNA661544.
EXPERIMENTAL MODELS AND SUBJECT DETAILS
Ethics and biosafety
The generation of recombinant SARS-CoV-2 MA and in vivo passaging was approved for use under BSL3 conditions by the
University of North Carolina at Chapel Hill Institutional Review Board (UNC-CH IBC) and by a Potential Pandemic Pathogen Care
and Oversight committee at the National Institute of Allergy and Infectious Diseases (NIAID). All animal work was approved by
Institutional Animal Care and Use Committee at University of North Carolina at Chapel Hill according to guidelines outlined by the
Association for the Assessment and Accreditation of Laboratory Animal Care and the U.S. Department of Agriculture. All work
was performed with approved standard operating procedures and safety conditions for SARS-CoV-2. Our institutional BSL3 facilities
have been designed to conform to the safety requirements recommended by Biosafety in Microbiological and Biomedical Labora-
tories (BMBL), the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and
Prevention (CDC), and the National Institutes of Health (NIH). Laboratory safety plans have been submitted, and the facility has been
approved for use by the UNC Department of Environmental Health and Safety (EHS) and the CDC.
Cell lines
Simian kidney cell line Vero E6 (ATTC # CRL1586) was purchased from ATCC and preserved in our laboratory. Primary HBE cell cul-
tures were obtained from the Tissue Procurement and Cell Culture Core Laboratory in the Marsico Lung Institute/Cystic Fibrosis
Research Center at UNC. Human tracheobronchial epithelial cells provided by Dr. Scott Randell were obtained from airway speci-
mens resected from patients undergoing surgery under University of North Carolina Institutional Review Board-approved protocols
(#03-1396) by the Cystic Fibrosis Center Tissue Culture Core. HBEs were generated by differentiation at an air-liquid interface for 6 toCell 183, 1–16.e1–e6, November 12, 2020 e3
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Resource8 weeks to form well-differentiated, polarized cultures that resembled in vivo pseudostratified mucociliary epithelium (Fulcher
et al., 2005).
Virus strains
The virus strains icSARS-CoV-2 WT (Hou et al., 2020), icSARS-CoV-2 MA (Dinnon et al., 2020), and icSARS-CoV-2-nLuc (Dinnon
et al., 2020) stocks were generated in our laboratory. SARS-CoV-2 MA10 was generated in this study via serial lung passaging in
mice for 10 passages. Briefly, mice were infected with the SARS-CoV-2 MA stock virus (Dinnon et al., 2020) for the first passage
and with lung homogenates of the previous passage for all following passages (passage 2 – 10). Clonal isolate from P10 was plaque
purified to obtain SARS-CoV-2MA10. All virus stocks were propagated on Vero E6 cells in minimal essential medium containing 10%
fetal bovine serum (HyClone) and supplemented with penicillin/kanamycin (GIBCO). Virus plaques were visualized by neutral red
staining for two to three days. All viral infections were conducted under biosafety level 3 (BSL-3) conditions at negative pressure
and personnel was protected wearing Tyvek suits connected to personal powered-air purifying respirators.
Mouse strains
10-week and 1-year old female BALB/c/cAnNHsdmicewere purchased fromEnvigo (strain 047), 10-week old female C57BL/6Jmice
were purchased from Jackson Laboratory (strain 000664), and 10-week old female andmale IFNR DKOmice were obtained from the
Whitmire Laboratory and bred at the University of North Carolina at Chapel Hill. All animal work was approved by Institutional Animal
Care and Use Committee at University of North Carolina at Chapel Hill under protocol 19-168 according to guidelines outlined by the
Association for the Assessment and Accreditation of Laboratory Animal Care and the U.S. Department of Agriculture. All infection
studies were performed in animal biosafety level 3 (BSL-3) facilities at University of North Carolina at Chapel Hill.
METHOD DETAILS
Viruses and cells
The parental SARS-CoV-2 MA virus was derived from an infectious clone of SARS-CoV-2 and further genetically engineered to intro-
duce Q498Y/P499T substitutions into the spike protein (Dinnon et al., 2020). Passage 1 SARS-CoV-2WT andMA stocks were grown
using Vero E6 cells and titered via plaque assay. Briefly, serially diluted virus was added to amonolayer of Vero E6 cells and overlayed
with media containing 0.8% agarose. After three days plaques were visualized via staining with Neutral Red dye and counted.
Vero E6 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, GIBCO), 5% Fetal Clone II serum (Hyclone), and 1X
antibiotic/antimycotic (GIBCO). For single step growth curves, cells were infectedwith amultiplicity of infection (MOI) of 0.5 for 1 hour.
After removal of inoculum, cells were washed twice with PBS and 2mL of media added. At designated time points supernatant was
harvested and stored at80C until further analysis. Well differentiated primary human bronchiolar airway epithelial (HBE) cells were
cultured in ALI media. In order to generate a growth curve, cells were infected with a MOI of 0.5 for 2 hours after which the inoculum
was removed, cells were rinsed three times with PBS and replaced with media. At designated time points, HAEs were apically
washed with 200 mL 1X PBS for 10 minutes and samples stored at 80C until further analysis.
Clonal isolate from P10 was plaque purified from a plaque assay of a P10-infected mouse lung homogenate via inoculation of Vero
E6 cells with an agar stab, generating a passage 1 SARS-CoV-2 MA10 stock. A passage 2 stock was grown, and supernatant viral
RNA was sequenced (described below). A larger passage 3 stock was grown, titered, and used for all subsequent experiments.
Sequencing (library preparation and SNP detection)
Viral RNA from clarified cell culture supernatant was isolated using TRIzol LS (Invitrogen) using a Direct-zol RNA Kit (Zymo Research)
following manufacturers suggested protocol and quantified by NanoDrop (ThermoFisher Scientific). dsDNA was synthesized by
random priming with Random Primer 9 (New England BioLabs) on 500-1000 ng of each isolate’s RNA and reverse transcribed using
Super Script II (Sigma-Aldrich) to make cDNA followed by second strand synthesis using NEBNext Ultra II Non-Directional RNA Sec-
ond Strand Synthesis Module (New England BioLabs) following the manufacturer’s suggested protocols. dsDNA was quantified us-
ing Qubit dsDNA HS Assay Kit (ThermoFisher Scientific). Libraries were prepared using Nextera XT DNA Library Preparation Kits (Il-
lumina) and sequenced on a NovaSeq 6000 System (Illumina) with paired end reads (23 151). SARS-CoV-2 MA10 passage 2 reads
were de novo assembled using CLC Genomics Workbench v12 (QIAGEN) to confirm initial viral sequence.
RNA in situ hybridization
RNA-ISHwas performed on paraffin-embedded 4 mm tissue sections using the RNAscopeMultiplex Fluorescent Assay v2, according
to the manufacturer’s instructions (Advanced Cell Diagnostics). Tissue sections were deparaffinized with xylene (2 changes3 5 min)
and 100% ethanol (2 changes3 1 min), and then incubated with hydrogen peroxide for 10 min, followed by target retrieval in boiling
water for 15 min, and incubation with Protease Plus (Advanced Cell Diagnostics) for 15 min at 40C. Slides were hybridized with
custom probes at 40C for 2 hours, and signals were amplified according to themanufacturer’s instructions. An Olympus VS200 fluo-
rescent microscope and Olympus confocal microscope were utilized to capture the stained sections.e4 Cell 183, 1–16.e1–e6, November 12, 2020
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Immunohistochemical staining was performed on paraffin-embedded 4 mm tissue sections according to a protocol as previously
described (Okuda et al., 2019). Briefly, paraffin-embedded sections were baked at 60 C for 2–4 hours, and deparaffinized with
xylene (2 changes3 5 min) and graded ethanol (100% 23 5 min, 95% 13 5 min, 70% 13 5 min). After rehydration, antigen retrieval
was performed by boiling the slides in 0.1 M sodium citrate pH 6.0 (3 cycles with microwave settings: 100% power for 6.5 min, 60%
for 6 min, and 60% for 6 min). After cooling and rinsing with distilled water, quenching of endogenous peroxidasewas performedwith
0.5%hydrogen peroxide inmethanol for 15 min, slides washed in PBS, and blockedwith 4%normal donkey serum, for an hour at RT.
Primary antibodies were diluted in 4% normal donkey serum in PBST and incubated over night at 4 C. Species-matched gamma
globulin was used as an isotype control at the same concentration as the primary antibody. Sections were washed in PBST and Spe-
cies-matched secondary antibodies were applied for 60 min at RT. After washing in PBST, the Vector TrueVIEW Autofluorescence
Quenching Kit (Vector laboratories) was used to reduce background staining, and glass coverslips were placed over tissue sections
with the ProLong Gold Antifade Reagent with DAPI (Invitrogen). Coverslipped slides were scanned and digitized using an Olympus
VS200 whole slide scanner microscope.
In vivo infection
BALB/cAnNHsd mice were obtained from Envigo (strain 047). C57BL/6J mice were obtained from the Jackson Laboratory (strain
000664). Type I and II interferon receptor double knock out (IFNR DKO) mice were originally obtained from the Whitmire laboratory
and bred at the University of North Carolina at Chapel Hill. Anesthetized (ketamine/xylazine) mice were intranasally infected with 105
PFU SARS-CoV-2 MA and different doses of SARS-CoV-2 MA10 diluted in PBS where indicated. Clinical signs of disease (weight
loss and lung function) were monitored daily. Lung function was assessed utilizing whole body plethysmography (WBP; DSI Buxco
respiratory solutions, DSI Inc.) by allowingmice to acclimate inWBPchambers for 30minutes followed by 5minutes of data recording
as described previously (Menachery et al., 2015). Acquired data was analyzed using FinePointe software. Mice were euthanized by
isoflurane overdose at indicated time points when samples for titer (caudal right lung lobe) and histopathological analyses (left lung
lobe) were collected. All animals in this manuscript that are recorded as ‘‘dead’’ were either found dead in cage or weremoribund and
euthanized as they approached 70% of their starting body weight which is the defined human endpoint according to the respective
animal protocol. Importantly, mice were randomized and assigned to specific harvest days before the start of the experiment. Lung
viral titers were determined by plaque assay. Briefly, right caudal lung lobes were homogenized in 1mL PBS using glass beads and
serial dilutions of the clarified lung homogenateswere added to amonolayer of Vero E6 cells. After three days plaqueswere visualized
via staining with Neutral Red dye and counted. The left lung lobe was stored in 10% phosphate buffered formalin for 7 days prior to
removal from the BSL3 for processing. After paraffin embedding, sectioning and staining histopathological scoring was performed.
Chemokine & Cytokine analysis
BioPlex Pro mouse cytokine 23-plex assay (Bio-Rad) was utilized to analyze chemokines and cytokines in serum and lung samples
from 1-year-old BALB/c mice according to manufacturer’s protocol. 50 mL of clarified lung samples or 50 mL of 1:4 diluted serum
samples were incubated with magnetic capture beads, washed, incubated with detection antibodies and SA-PE. Cytokines were
recorded on a MAGPIX machine (Luminex) and quantitated via comparison to a standard curve. xPONENT software was used for
data collection and analysis.
Histological analysis and antigen staining
Immediately after euthanasia, the left lung lobe was harvested and fixed by submersion in 10% phosphate buffered formalin for 7 days.
Fixed tissues were routinely processed on a Leica ASP 6025, embedded in paraffin (Leica Paraplast) and sectioned at 4um thickness.
Sequential sectionswere stainedwith hematoxylin and eosin (Richard Allan Scientific) and stained for SARS-CoV-2 nucleocapsid using
a monoclonal anti-SARS-CoV nucleocapsid antibody (NB100-56576, Novus Biologicals) on the Ventana Discovery platform (Roche).
Briefly, antigen retrieval was performed using Ventana’s CC1 (pH 8.5), tissues were blocked, primary antibody diluted at 1:250 using
Discovery Casein Diluent (760-219, Roche), ready-to use secondary antibody (Discovery OmniMap anti Rabbit HRP, 760-4311), fol-
lowed by DAB development and Hematoxylin II staining. Pathology was evaluated and scored by a board-certified veterinary pathol-
ogist (S.A.M). Lung histopathology was blindly scored using three 600X fields per tissue as previously described. Briefly, three random
fields of diseased tissue at 600X total magnification (60X objective x 10X eyepiece) were chosen and scored in a blindedmanner for ALI
and DAD histological scoring systems. For the ASL/ALI scoring system the following parameter were analyzed: (A) neutrophils in the
alveolar space (none = 0, 1-5 cells = 1, > 5 cells = 2); (B) neutrophils in the interstitial space/septae (none = 0, 1-5 cells = 1, > 5 cells =
2); (C) hyaline membranes (none = 0, one membrane = 1; > 1 membrane = 2); (D) proteinaceous debris in air spaces (none = 0, one
instance = 1, > 1 instance = 2); (E) alveolar septal thickening (> 2x mock thickness = 0, 2-4x mock thickness = 1, > 4xmock thickness =
2). Scoreswere calculated as followed: [(20 x A) + (14 x B) + (7 x C) + (7 x D) + (2 x E)] / 100. Final scoreswere obtained by averaging three
fields per mouse. The defuse alveolar damage (DAD) scores were determined as followed: 1 = absence of cellular sloughing and ne-
crosis; 2 = uncommon solitary cell sloughing and necrosis; 3 =multifocal (3 + foci) cellular sloughing and necrosiswith uncommon septal
wall hyalinization; 4 =multifocal (> 75%of field) cellular sloughing and necrosiswith commonand/or prominent hyalinemembranes. The
average of three fields determined the final DAD score per mouse. An Olympus BX43 light microscope was used to capture images at
200X magnification with a DP27 camera using cellSens Dimension software.Cell 183, 1–16.e1–e6, November 12, 2020 e5
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ResourceVaccination and neutralization studies
Micewere vaccinatedwith Venezuelan equine encephalitis virus strain 3526 based replicon particles (VRPs) expressing SARS-CoV-2
spike (S), nucleocapsid (N), or GFP as control. VRPs were given via hind footpad injection at a dose of 103 in 10 mL. The same strategy
was used to boost mice 3 weeks post prime and presence of neutralizing antibodies was confirmed in submandibular bleeds at the
time of boost.
Authentic virus neutralization of sera from 3 weeks post boost using nanoLuciferase-expressing SARS-CoV-2 virus (SARS-CoV-2
nLuc), bearing wild-type spike protein, was performed as described with slight modification (Hou et al., 2020; Dinnon et al., 2020).
Briefly, Vero E6 cells were seeded at 2x104 cells/well in a 96-well plate 24h before the assay. 100 PFU of SARS-CoV-2-nLuc virus
were mixed with serial diluted sera at 1:1 ratio and incubated at 37C for 1h. A 8-point, 3-fold dilution curve was generated for
each sample with starting concentration at 1:20. Virus and Abmix was added to cells and incubated at 37C + 5%CO2 for 48h. Lucif-
erase activities were measured by Nano-Glo Luciferase Assay System (Promega, WI) following manufacturer protocol using Spec-
traMax M3 luminometer (Molecular Device). Percent inhibition and 50% inhibition concentration (IC50) were calculated by the
following equation: [1-(RLU with sample/ RLU with mock treatment)] x 100%. Fifty percent inhibition titer (IC50) was calculated in
GraphPad Prism 8.4.2 by fitting the data points using a sigmoidal dose-response (variable slope) curve.
Intranasal challenge of anesthetized (ketamine/xylazine) mice with 104 PFU SARS-CoV-2 MA10 was performed 4 weeks post
boost. Changes in body weight and alterations in lung function parameters were recorded daily and mice were euthanized by iso-
flurane overdose for harvests on day 2 and day 4 after infection. Viral titers in lungs were analyzed via plaque assay.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data visualization and analyses were performed using build-in functions of GraphPad Prism. Specific statistical tests, numbers of
animals, and definitions of center, dispersion and precision measures are mentioned in respective figure legends. For the character-
ization of SARS-CoV-2 MA10 in young and old BALB/c as well as young C57BL/6 mice the following statistical tests were used:
mixed effect analysis followed by Sidak’s multiple comparisons was used to analyze weight loss and whole body plethysmography
data; cell growth curves and cytokine / chemokine responses were analyzed by 2-factor ANOVA followed by Sidak’s multiple correc-
tion; gross lung congestions scores, lung and nasal titers, as well as DAD and ATS / ALI scores were analyzed by 2-factor ANOVA
followed by Sidak’s multiple comparisons; survival rates were analyzed by log rank test. For the IFNR-DKO data the following sta-
tistical tests were used: weight loss data was analyzed using mixed effect analysis followed by Sidak’s multiple comparisons; 2-fac-
tor ANOVA followed by Tukey’s multiple comparisons was used for gross congestion scores and lung / nasal titer data; whole body
plethysmography was analyzed via 2-factor ANOVA followed by Sidak’s multiple comparisons. VRP mouse data was analyzed as
followed: weight loss and whole body plethysmography data was analyzed via mixed effect analysis followed by Sidak’s multiple
comparisons; neutralization data was log transformed and analyzed via 1-factor ANOVA followed by Holm-Sidak’s multiple compar-
ison; lung / nasal titer data as well as whole body plethysmography was analyzed by 2-factor ANOVA followed by Dunnetts multiple
comparisons; unpaired, two-tailed Student’s t test was used for comparisons of serum IC50 values from 10-week and 1-year-old
vaccinated mice; Comparison of serum IC50 values from 10-week-old spike vaccinated mice to neutralize SARS-CoV-2 WT versus
SARS-CoV-2 MA was analyzed via Wilcoxon matched-pairs signed rank test.e6 Cell 183, 1–16.e1–e6, November 12, 2020
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Figure S1. SARS-CoV-2 MA10 Does Not Replicate in Non-Respiratory Tract Tissues, Related to Figure 3
Analysis of non-respiratory tract tissues of SARS-CoV-2 MA10 infected 1-year-old female BALB/c mice at 2dpi from Figure 3. (A) Viral titer in serum, heart, and
brain. Dotted line represents limit of detection. Undetected samples are plotted at half the limit of detection. (B-F) Representative hematoxylin & eosin (left) and
IHC for viral nucleocapsid (right) images of heart (B), liver (C), small intestine (D), kidney (E), and spleen (F). Faint non-specific IHC staining in spleen is result of red
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Figure S2. SARS-CoV-2 MA10 Induces Local and Systemic Cytokine and Chemokine Responses, Related to Figure 3
(A-B) Cytokine and chemokine analysis of mock or SARS-CoV-2 MA10 infected 1-year-old BALB/c mice from Figure 3. Serum and lung homogenate were
assayed for 23 cytokines and chemokines at 2dpi (A) and 4dpi (B). n = 4mock and 5MA10mice at each time point. Data analyzed by 2-factor ANOVA followed by
Sidak’s multiple comparisons. Asterisks represent p < 0.05.
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Figure S3. SARS-CoV-2 MA10 Infects the Nasal Olfactory Epithelium but Not Olfactory Sensory Neurons, Related to Figure 3
SARS-CoV-2 MA10 cellular tropism in the nasal cavity was assessed by RNA in situ hybridization (ISH) infected female 1-year-old BALB/c mice from Figure 3 at
2dpi.Uchl1 is a marker of olfactory sensory neurons (OSNs). (i & iii and ii and iv) are single color channels shownmerged in (v and vi). Scale bars represent 200 mm
(i, iii, v) or 10 mm (ii, iv, vi).
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Figure S4. Virus Replicon Particle Delivered Spike Vaccination Protects Young Mice from SARS-CoV-2 MA10 Challenge, Related to Figure 6
10-week-old female BALB/c mice were vaccinated with 103 virus replicon particles (VRPs) expressing SARS-CoV-2 wild-type spike (S, n = 10), nucleocapsid (N,
n = 10), or GFP (n = 10). Mice received a boost 3 weeks after prime immunization and submandibular blood samples were taken to be analyzed via neutralization
assays. All mice were challenged 4 weeks after the boost immunization. (A) Neutralization of SARS-CoV-2 WT by sera from vaccinated mice 3 weeks post boost.
ID50: inhibitory concentration necessary to achieve 50% virus neutralization. Dotted line represents limit of detection. Undetected samples are plotted at half the
limit of detection. Log transformed data analyzed via 1-factor ANOVA followed by Holm-Sidak’s multiple comparisons. (B) Comparison of serum IC50 values from
10-week and 1-year-old spike vaccinatedmice from Figure 6A. Dotted line represents limit of detection. Data analyzed by unpaired, two-tailed Student’s t test. (C)
Comparison of serum IC50 values from 10-week-old spike vaccinated mice to neutralize SARS-CoV-2 WT versus SARS-CoV-2 MA. Data analyzed by Wilcoxon
matched-pairs signed rank test. Data not statistically significant. (D) Percent starting weight. Data analyzed bymixed effects analysis followed by Sidak’s multiple
comparisons. (E) Survival rate of mice from (D). (F-G) Viral lung (F) and nasal cavity (G) titer. n = 5 for each group at each time point. Dotted line represents limit of
detection. Undetected samples are plotted at half the limit of detection. Log transformed data analyzed via 2-factor ANOVA followed by Dunnett’s multiple
comparisons. (G-I) Whole body plethysmography analysis of lung function parameters (n = 5 mice per group at 0dpi): PenH (G), Rpef (H), and EF50 (I). Data
analyzed using 2-factor ANOVA followed by Dunnett’smultiple comparisons. Error bars represent standard error of themean about themean. Asterisks represent
p < 0.05.
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